There are currently 805 clinical trials in Detroit, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including Henry Ford Hospital, Henry Ford Health System, Barbara Ann Karmanos Cancer Institute and Karmanos Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Intermittent Bolus vs Continuous Infusion Via ESP Catheters RCT
NCT05642416
Recruiting
The purpose of this prospective randomized controlled trial is to compare the effectiveness of two different delivery methods for postoperative pain management following cardiac surgery requiring median sternotomy: intermittent programmed LA bolus versus continuous LA infusion through ESP catheters. Effectiveness of analgesia will be assessed based on the subjects' NRS pain scores and opioid consumption. The primary outcome measure will be the patients' opioid consumption over the course of the... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/03/2024
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Post Operative Pain
Register for Updates
Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
NCT04838041
Recruiting
This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have previously attempted to discontinue Tyrosine Kinase inhibitors (TKI). All patients must have restarted the same TKI they were on prior to discontinuation at the time of relapse in order to be eligible for this trial.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: The Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Chronic Phase Chronic Myelogenous Leukemia
Register for Updates
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
NCT03842696
Recruiting
The purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic blood or marrow transplant (BMT) and determine whether the addition of Vorinostat to the standard graft versus host disease (GVHD) prophylaxis will reduce the incidence of GVHD.
Gender:
All
Ages:
Between 3 years and 39 years
Trial Updated:
04/01/2024
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Hematologic Diseases, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia, Blastic Phase, Myelodysplastic Syndromes, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma, Graft Vs Host Disease, Graft-versus-host-disease, Acute Leukemia in Remission
Register for Updates
Predictors of Post-COVID Clinical and Cognitive Consequences
NCT06291870
Recruiting
The CDC describes Post-acute sequelae of SARS-COV-2 infection (PASC) for the wide range of physical and mental health consequences experienced by some patients. These sequelae may be present four or more weeks after SARS-COV-2 infection, including patients who had initial mild or asymptomatic acute infection. However, there is complete absence of data whether chronic sleep changes due to COVID-19 infection may influence these physical and mental health consequences. While fatigue is one of the c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan
Conditions: Post Acute Sequelae of SARS CoV 2 Infection, Obstructive Sleep Apnea
Register for Updates
Assessment of Breast Cancer Patients Satisfaction and Health Related Quality of Life Outcomes
NCT03333122
Recruiting
The purpose of the study is to learn more about the quality of life and satisfaction with breast cancer surgical treatment and education from patient reported outcome data. The data and information obtained from breast cancer patients can be invaluable in counselling patients with a new diagnosis of breast cancer on their expected outcomes and results. The hypothesis is that using prospectively obtained data to guide surgical decision-making and optimize access to surgical procedures would impro... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Breast Cancer Female
Register for Updates
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
NCT05064540
Recruiting
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Gender:
All
Ages:
21 years and above
Trial Updated:
03/28/2024
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: AAA, AAA - Abdominal Aortic Aneurysm
Register for Updates
Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
NCT04283097
Recruiting
This is a phase 1, multicenter, open-label, multiple-ascending dose study to evaluate the safety, pharmacokinetics and clinical activity of KPG-818 in subjects with hematological malignancies. Approximately 30 patients will be enrolled for dose escalation of 4 dose levels. Indication: Hematological malignancies (multiple myeloma [MM], mantle cell lymphoma [MCL], diffuse large B-cell lymphoma [DLBCL], adult T-cell leukemia-lymphoma [ATL], and indolent non Hodgkin lymphomas such as follicular lym... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: Henry Ford Health System - Hemophilia and Thrombosis Treatment Center, Detroit, Michigan
Conditions: Hematological Malignancies
Register for Updates
Cold Agglutinin Disease Real World Evidence Registry
NCT05791708
Recruiting
This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study. Patients with CAD who have been enrolled in previous sutimlimab clinical trials (e.g., BIVV009-01/LTS16214 [NCT02502903,CAD patients], BIVV009-03/EFC16215 [NCT03347... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Henry Ford Hospital Site Number : 1232, Detroit, Michigan
Conditions: Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
Register for Updates
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT02632448
Recruiting
The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Endometrial Cancer, Soft Tissue Sarcoma, Triple Negative Breast Cancer, Pancreas Cancer, Pancreatic Cancer
Register for Updates
Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty
NCT06234631
Recruiting
The goal of this study is to better understand how daily treatment with cannabidiol (CBD) affects the need for opioid pain medication, as well as pain, inflammation and other related symptoms, after knee replacement surgery. The information collected in this study is necessary to help understand whether CBD may be a useful medication before and/or after surgery. The study hypothesis is that CBD exerts opioid-sparing effects through anti-inflammatory, analgesic, and anxiolytic mechanisms.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/19/2024
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Knee Replacement Surgery, Osteoarthritis, Knee
Register for Updates
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
NCT04479267
Recruiting
This phase II trial studies how well polatuzumab vedotin and combination chemotherapy work in treating patients with previously untreated double, triple hit lymphoma, Double Expressor Lymphoma or High-Grade B Cell Lymphoma. Polatuzumab vedotin is a monoclonal antibody that works by binding with cancer cells and releasing another chemotherapy drug, called monomethyl auristatin E, into the cell causing the cancer cells to die or stop growing. Chemotherapy drugs, such as rituximab, cyclophosphamide... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements, Double Expressor Lymphoma, High-grade B-cell Lymphoma
Register for Updates
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
NCT03147885
Recruiting
This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell Non-Hodgkin's lymphoma called R-CHOP. The investigators will establish maximum tolerated dose of Selinexor in combination with RCHOP and also study the efficacy of this combination for therapy of B cell Non-Hodgkin's lymphoma. Giving Selinexor plus chemotherapy may work better in treating patients with B cell non-Hodgkin lym... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Extranodal Marginal Zone Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Stage III Non-Hodgkin Lymphoma, Stage IV Non-Hodgkin Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma
Register for Updates